Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

Lyra Therapeutics Inc. has scored a clinical trial win with its sinus inflammation treatment that sent its stock soaring ...

The approval of the mNEXSPIKE vaccine comes less than a week after Health and Human Services Secretary, Robert F. Kennedy Jr. announced the COVID vaccine for healthy children and healthy pregnant ...

Julie Brill, chief privacy officer and corporate vice president for Global Privacy, Safety, and Regulatory Affairs at ...

Moderna’s newest lower-dose COVID-19 vaccine is approved for all adults 65 and older, and for people aged 12 to 64 who are at ...

Shares of [U.S. steelmakers surged]( ...

Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40 ...

The FDA approved a new Moderna COVID-19 vaccine for adults 65 and older. "We were told that pain was temporary. As it turns ...

KEY TAKEAWAYS U.S. equities were mixed at midday after China accused the U.S. of violating a trade deal the two countries ...

The new mRNA vaccine encodes the receptor-binding domain and the N-terminal domain of the SARS-CoV-2 spike protein ...

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.